The construction and validation of a frailty risk prediction model for older adults with lung cancer : A cross-sectional study

Copyright © 2023 Elsevier Ltd. All rights reserved..

OBJECTIVE: We aimed to construct and internally validate a frailty risk prediction model in older adults with lung cancer.

METHOD: In total, 538 patients were recruited in a grade A tertiary cancer hospital in Tianjin, and patients were randomly divided into the training group (n = 377) and the testing group (n = 166) at a ratio of 7:3. The Frailty Phenotype scale was used to identify frailty and logistic regression analysis was used to identify the risk factors and establish a frailty risk prediction model.

RESULTS: In the training group, logistic regression showed that age, fatigue-related symptom cluster, depression, nutritional status, D-dimer level, albumin level, presence of comorbidities, and disease course were independent risk factors for frailty. The areas under the curve (AUCs) of the training and testing groups were 0.921 and 0.872, respectively. A calibration curve of P = 0.447 validated model calibration. The decision curve analysis demonstrated greater clinical benefit when the threshold probability was >20%.

CONCLUSION: The prediction model had a favorable prediction power for determining the risk of frailty, contributing to the prevention and screening of frailty. Patients with a frailty risk score of more than 0.374 should be regularly monitored for frailty and receive personalized preventive interventions.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:64

Enthalten in:

European journal of oncology nursing : the official journal of European Oncology Nursing Society - 64(2023) vom: 15. Juni, Seite 102316

Sprache:

Englisch

Beteiligte Personen:

Hou, Ying-Ge [VerfasserIn]
Feng, Shu-Mei [VerfasserIn]
Wang, Song-Mei [VerfasserIn]
Zhao, Ya-Jie [VerfasserIn]
Yan, Ling [VerfasserIn]

Links:

Volltext

Themen:

Aged
Frailty
Journal Article
Lung neoplasms
Prevalence
Randomized Controlled Trial
Risk factor

Anmerkungen:

Date Completed 19.06.2023

Date Revised 19.06.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.ejon.2023.102316

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM356449335